In the new guidance for cannabis-based medicinal products NICE recommend Sativex as a 4 week trial to treat moderate to severe spasticity in adults with multiple sclerosis, if other pharmacological treatments for spasticity are not effective (see the recommendations on spasticity in NICE's guideline on multiple sclerosis in adults), and the company provides the product according to its pay-for-responders scheme. After the 4-week trial, the spray may be continued if the person has had at least a 20% reduction in spasticity-related symptoms on a 0 to 10 patient-reported numeric rating scale.